Outcome of Board Meeting
KIMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
KIMS's board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, with an unmodified opinion from S.R. Batliboi & Associates LLP. Consolidated revenue grew ~21.5% to Rs. 30,351 Mn (from Rs. 24,982 Mn) and consolidated profit after tax rose ~23.5% to Rs. 4,148 Mn (from Rs. 3,359 Mn). Standalone PAT grew ~28.5% to Rs. 3,029 Mn. The company completed the 100% acquisition of Chalasani Hospitals (Queen's NRI Hospital) for Rs. 1,112 Mn during the year and recognized a Rs. 108 Mn exceptional gain on call option valuation. The board also appointed IKR & Associates as Secretarial Auditors (5-year term), re-appointed Mrs. Y. Prameela Rani as Independent Director (5-year second term), and fixed the 23rd AGM for August 29, 2025.
Strong consolidated revenue growth above 20% and healthy PAT growth signal robust operational performance and the Queen's NRI Hospital acquisition is already contributing. The clean audit report and no negative cash flow concerns are positive for shareholders; consolidated EPS rose to Rs. 9.61 (restated) from Rs. 7.75.